4.5 Article

Potent inhibition of human apurinic/apyrimidinic endonuclease 1 by arylstibonic acids

Journal

MOLECULAR PHARMACOLOGY
Volume 73, Issue 3, Pages 669-677

Publisher

AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/mol.107.042622

Keywords

-

Funding

  1. NCI NIH HHS [N01CO12400, N01-CO-12400] Funding Source: Medline
  2. NIGMS NIH HHS [GM56834, R01 GM056834, R01 GM056834-12] Funding Source: Medline

Ask authors/readers for more resources

Human apurinic/apyrimidinic endonuclease (Ape1) plays an important role by processing the > 10,000 highly toxic abasic sites generated in the genome of each cell every day. Ape1 has recently emerged as a target for inhibition, in that its overexpression in tumors has been linked with poor response to both radiation and chemotherapy and lower overall patient survival. Inhibition of Ape1 using siRNA or the expression of a dominant-negative form of the protein has been shown to sensitize cells to DNA-damaging agents, including various chemotherapeutic agents. However, potent small-molecule inhibitors of Ape1 remain to be found. To this end, we screened Ape1 against the NCI Diversity Set of small molecules and discovered aromatic nitroso, carboxylate, sulfonamide, and arylstibonic acid compounds with micromolar affinities for the protein. A further screen of a 37-compound arylstibonic acid sublibrary identified ligands with IC50 values in the range of 4 to 300 nM. The negatively charged stibonic acids act by a partial-mixed mode and probably serve as DNA phosphate mimics. These compounds provide a useful scaffold for development of chemotherapeutic agents against Ape1.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available